GeneTex’s “5 + 1” Pillar Antibody Validation Plan

In conjunction with its shift to recombinant antibody production, GeneTex is incorporating enhanced validation protocols based on guidelines published by the International Working Group for Antibody Validation (IWGAV) into its manufacturing and quality assurance (QA) workflow (1). This involves evaluation of each antibody using at least one, and frequently more, of five validation “pillars” defined in the IWGAV study. GeneTex’s version of the IWGAV plan follows the five standard strategies and includes (1) Knockout/Knockdown; (2) Comparable Antibodies; (3) Immunoprecipitation followed by Mass Spectrometry (IP/MS); (4) Biological and Orthogonal Validation; and (5) Recombinant Protein Expression. The company refers to this as its “5+1” Pillar Plan when referencing new recombinant antibody production, with the “+1” designation referring to the pre-validation that occurs with clone selection during the recombinant antibody production process. It is also working to apply IWGAV Five Pillar validation to other products already in the catalog. GeneTex is making significant progress in this ambitious task, as noted in a CiteAb blog from October, 2022 (2).

Antibody fidelity, application-dependent reliability, and performance and supply consistency are crucial for ensuring research integrity. GeneTex strives to create reagents that researchers can trust. Please contact us or visit www.genetex.com to learn more.